AstraZeneca has struck a deal to acquire biotechnology EsoBiotec for up to $1bn, as the London-listed pharmaceuticals group ...

Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

Regina Toomey Bueno, former oncology admin at Garnet Health, had good insurance, lots of support, and 2 cancer diagnoses. She ...

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...

March is Myeloma Awareness Month, a time to recognize the subtle but serious symptoms of multiple myeloma, including persistent fatigue, unexplained bone pain and anemia. Since diagnosis is often ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.

The International Myeloma Foundation (IMF) is excited to announce that the 2nd annual Iceland Cycling Expedition (ICE)—a 6-night/7-day endurance fundraiser biking expedition —will take place from ...

Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...